Relmada Therapeutics, Inc. (RLMD) shareholders
RLMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$4.21+0.05 (+1.20%)
Close on Nov 13, 2026Market cap $449.08MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
94.0%
100M of 107M shares
Institutional holders
126
47 new, 23 sold out
Net institutional buying
26M
In Q2 2026
Insider trades, 12 months
6 buys · 0 sales
Net bought $1.83M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Janus Henderson Group PLC | 7,439,415 | 10.10% | 13G (passive) | Jan 30, 2026 |
| BlackRock, Inc. | 7,352,913 | 7.00% | 13G (passive) | Jun 30, 2026 |
| Squadron Master Fund LP Joint filing with Squadron Capital Management LLC (7.00%), Matthew Sesterhenn (7.00%) and 1 more | 7,350,000 | 7.00% | 13G (passive) amendment | Jun 30, 2026 |
| VHCP Management III, LLC Joint filing with Venrock Healthcare Capital Partners III, L.P. (6.20%), VHCP Co-Investment Holdings III, LLC (6.20%) and 4 more | 6,508,433 | 6.20% | 13G (passive) | Jun 2, 2026 |
| Commodore Capital LP Joint filing with Commodore Capital Master LP (5.10%), Robert Egen Atkinson (5.10%) and 1 more | 5,505,527 | 5.10% | 13G (passive) | Apr 27, 2026 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (5.82%), Phillip Gross (5.82%) | 4,270,000 | 5.82% | 13G (passive) | Dec 31, 2025 |
| Simon Basseyn Joint filing with Spruce Street Capital LP (5.57%), Alex R. Rosen (5.57%) | 4,086,181 | 5.57% | 13G (passive) | Dec 31, 2025 |
| William Blank Joint filing with Squadron Capital Management LLC (9.90%), Squadron Master Fund LP (8.80%) | 3,298,500 | 9.90% | 13G (passive) amendment | Jun 30, 2025 |
| Squadron Capital Management LLC Joint filing with William Blank (6.20%), Squadron Master Fund LP (5.50%) | 2,050,000 | 6.20% | 13G (passive) | Apr 24, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of RLMD | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 11,164,803 | 10.47% | $77.32M | New | 0.03% |
| BlackRock, Inc. | 7,426,780 | 6.96% | $51.39M | +6,137,230 | 0.00% |
| Squadron Capital Management LLC | 7,350,000 | 6.89% | $50.86M | −1,124,571 | 15.78% |
| VR Adviser, LLC | 6,844,305 | 6.42% | $47.36M | +2,000,925 | 1.44% |
| Spruce Street Capital LP | 6,391,328 | 5.99% | $44.23M | +129,214 | 8.68% |
| Adage Capital Partners Gp, L.L.C. | 4,763,158 | 4.47% | $32.96M | – | 0.05% |
| Vanguard Capital Management LLC | 4,460,210 | 4.18% | $30.86M | +1,383,640 | 0.00% |
| Jones Hill Capital LP | 3,655,075 | 3.43% | $25.29M | +3,312,323 | 5.38% |
| Orbimed Advisors LLC | 3,631,195 | 3.40% | $25.13M | −1,084,669 | 0.47% |
| State Street Corp | 2,517,550 | 2.36% | $17.42M | +2,160,510 | 0.00% |
| Geode Capital Management, LLC | 2,492,573 | 2.34% | $17.25M | +1,643,890 | 0.00% |
| Millennium Management LLC | 2,361,827 | 2.21% | $16.34M | −1,545,438 | 0.01% |
| Marshall Wace, Llp | 2,246,839 | 2.11% | $15.55M | −2,234,767 | 0.01% |
| Ikarian Capital, LLC | 2,148,359 | 2.01% | $14.87M | −540,000 | 1.60% |
| Driehaus Capital Management LLC | 2,132,053 | 2.00% | $14.75M | – | 0.09% |
| Ameriprise Financial Inc | 1,937,972 | 1.82% | $13.41M | +347,026 | 0.00% |
| Eventide Asset Management, LLC | 1,858,416 | 1.74% | $12.86M | +1,016,310 | 0.17% |
| Balyasny Asset Management L.P. | 1,520,688 | 1.43% | $10.52M | +1,268,231 | 0.01% |
| Stempoint Capital LP | 1,460,093 | 1.37% | $10.10M | +265,275 | 1.74% |
| Commodore Capital LP | 1,425,000 | 1.34% | $9.86M | +791,099 | 0.59% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 126 | 100M | 94.0% | 47 / 36 | 22 / 23 | 40M | 14M |
| Q1 2026 | 103 | 85M | 80.0% | 37 / 27 | 25 / 10 | 40M | 5M |
| Q4 2025 | 78 | 52M | 48.5% | 35 / 23 | 7 / 1 | 44M | 0M |
| Q3 2025 | 44 | 8M | 7.3% | 2 / 13 | 12 / 8 | 3M | 0M |
| Q2 2025 | 50 | 5M | 5.0% | 13 / 6 | 13 / 7 | 2M | 3M |
| Q1 2025 | 44 | 6M | 5.8% | 8 / 4 | 14 / 12 | 0M | 3M |
| Q4 2024 | 48 | 8M | 7.9% | 7 / 11 | 20 / 28 | 1M | 5M |
| Q3 2024 | 69 | 13M | 11.9% | 7 / 11 | 25 / 15 | 2M | 2M |
| Q2 2024 | 79 | 14M | 13.0% | 6 / 15 | 31 / 19 | 1M | 2M |
| Q1 2024 | 93 | 15M | 13.8% | 19 / 22 | 25 / 9 | 3M | 2M |
| Q4 2023 | 83 | 14M | 12.9% | 14 / 27 | 19 / 16 | 3M | 4M |
| Q3 2023 | 88 | 15M | 14.1% | 7 / 11 | 40 / 14 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
67 funds held RLMD in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of RLMD | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,169,804 | 2.97% | $21.94M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,087,837 | 1.96% | $14.45M | 0.02% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,204,852 | 1.13% | $8.34M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,035,434 | 0.97% | $5.50M | 0.02% | Jul 31, 2026 |
| Eventide Healthcare & Life Sciences Fund | 1,016,310 | 0.95% | $7.03M | 0.39% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 865,607 | 0.81% | $5.99M | 0.04% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 788,718 | 0.74% | $4.19M | 0.36% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF | 655,062 | 0.61% | $4.53M | 1.06% | Jun 30, 2026 |
| AdvisorShares Psychedelics ETF | 438,901 | 0.41% | $3.04M | 6.84% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 379,189 | 0.36% | $2.73M | 0.01% | May 31, 2026 |
| iShares Micro-Cap ETF | 317,798 | 0.30% | $2.20M | 0.14% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 229,629 | 0.22% | $1.22M | 0.02% | Jul 31, 2026 |
| Master Small Cap Index Series | 176,772 | 0.17% | $1.22M | 0.02% | Jun 30, 2026 |
| iShares Core S&P Total U.S. Stock Market ETF | 163,750 | 0.15% | $1.13M | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 144,336 | 0.14% | $1.04M | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Sergio Traversa | Chief Executive Officer, Director | 1,500,000 | 1.41% | Sep 11, 2026 |
| Paul Edward Kelly | COO, Director | 502,295 | 0.47% | Dec 16, 2025 |
| Maged Shenouda | Chief Financial Officer | 1,000,000 | 0.94% | Sep 11, 2026 |
| Chuck Ence | CA and CO | 403,931 | 0.38% | Dec 16, 2025 |
| Charles J. Casamento | Director | 10,000 | 0.01% | Dec 16, 2025 |
| John Glasspool | Director | 75,000 | 0.07% | Dec 16, 2025 |
| Fabiana Fedeli | Director | – | – | Dec 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Sergio Traversa Chief Executive Officer, Director | Sep 10, 2026 | Buy | +100,000 | $4.10 | $410.00K | 1,500,000 |
| Maged Shenouda Chief Financial Officer | Sep 10, 2026 | Buy | +79,800 | $4.25 | $339.15K | 1,000,000 |
| Sergio Traversa Chief Executive Officer, Director | Sep 9, 2026 | Buy | +100,000 | $4.18 | $418.00K | 1,400,000 |
| Maged Shenouda Chief Financial Officer | Sep 9, 2026 | Buy | +120,200 | $4.20 | $504.84K | 920,200 |
| Maged Shenouda Chief Financial Officer | Dec 15, 2025 | Buy | +11,665 | $4.12 | $48.06K | 800,000 |
| Sergio Traversa Chief Executive Officer, Director | Dec 15, 2025 | Buy | +27,500 | $4.12 | $113.30K | 1,300,000 |
| Sergio Traversa Chief Executive Officer, Director | Nov 5, 2025 | Buy | +272,500 | $2.20 | $599.50K | 1,272,500 |
| Chuck Ence CAO and COO | Nov 5, 2025 | Buy | +136,000 | $2.20 | $299.20K | 403,931 |
| Maged Shenouda Chief Financial Officer | Nov 5, 2025 | Buy | +500,000 | $2.20 | $1.10M | 788,335 |
| Paul Edward Kelly Chief Operating Officer, Director | Nov 5, 2025 | Buy | +90,000 | $2.20 | $198.00K | 502,295 |
| Sergio Traversa Chief Executive Officer, Director | Aug 28, 2025 | Buy | +55,976 | $0.74 | $41.42K | 1,000,000 |
| Sergio Traversa Chief Executive Officer, Director | Aug 27, 2025 | Buy | +129,455 | $0.67 | $86.73K | 944,024 |
| Sergio Traversa Chief Executive Officer, Director | Aug 26, 2025 | Buy | +80,545 | $0.62 | $49.94K | 814,569 |
| Sergio Traversa Chief Executive Officer, Director | May 20, 2025 | Buy | +147,686 | $0.56 | $82.70K | 734,024 |
| Maged Shenouda Chief Financial Officer | May 20, 2025 | Buy | +60,000 | $0.52 | $31.20K | 288,335 |
| Sergio Traversa Chief Executive Officer, Director | May 19, 2025 | Buy | +30,000 | $0.50 | $15.00K | 586,338 |
| Maged Shenouda Chief Financial Officer | May 19, 2025 | Buy | +90,000 | $0.49 | $44.10K | 228,335 |
| Sergio Traversa Chief Executive Officer, Director | May 16, 2025 | Buy | +172,314 | $0.45 | $77.54K | 556,338 |
| Paul Edward Kelly Chief Operating Officer, Director | May 16, 2025 | Buy | +200,000 | $0.43 | $86.00K | 412,295 |
| Maged Shenouda Chief Financial Officer | May 16, 2025 | Buy | +50,000 | $0.44 | $22.00K | 138,335 |
| Chuck Ence CA and CO | May 16, 2025 | Buy | +228,961 | $0.45 | $103.03K | 267,931 |
| Charles J. Casamento Director | Oct 22, 2024 | Gift | −13,000 | – | – | 0 |
| Sergio Traversa Chief Executive Officer, Director | Sep 11, 2024 | Buy | +51,407 | $2.99 | $153.71K | 384,024 |
| Maged Shenouda Chief Financial Officer | Sep 11, 2024 | Buy | +24,120 | $2.95 | $71.15K | 88,335 |
| Sergio Traversa Chief Executive Officer, Director | Sep 10, 2024 | Buy | +33,014 | $2.75 | $90.79K | 332,617 |
| Maged Shenouda Chief Financial Officer | Sep 10, 2024 | Buy | +21,118 | $2.73 | $57.65K | 64,215 |
| Sergio Traversa Chief Executive Officer, Director | Sep 9, 2024 | Buy | +55,579 | $2.71 | $150.62K | 299,603 |
| Maged Shenouda Chief Financial Officer | Sep 9, 2024 | Buy | +8,194 | $2.55 | $20.89K | 43,097 |
| Charles J. Casamento Director | Sep 9, 2024 | Buy | +13,000 | $2.56 | $33.28K | 13,000 |
| Paul Edward Kelly Director | Sep 9, 2024 | Buy | +25,000 | $2.59 | $64.75K | 212,295 |
| Maged Shenouda Chief Financial Officer | Jan 31, 2024 | Buy | +6,875 | $4.06 | $27.91K | 34,903 |
| Chuck Ence CA and CO | Jan 31, 2024 | Buy | +13,670 | $4.05 | $55.36K | 38,970 |
| Sergio Traversa Chief Executive Officer, Director | Jan 31, 2024 | Buy | +27,460 | $4.00 | $109.84K | 244,024 |
| Maged Shenouda Chief Financial Officer | Jan 30, 2024 | Buy | +15,000 | $3.89 | $58.35K | 28,028 |
| Chuck Ence CA and CO | Jan 30, 2024 | Buy | +14,500 | $3.87 | $56.12K | 25,300 |
| Sergio Traversa Chief Executive Officer, Director | Jan 30, 2024 | Buy | +40,999 | $3.90 | $159.90K | 216,564 |
| Maged Shenouda Chief Financial Officer | Jan 29, 2024 | Buy | +10,800 | $3.65 | $39.42K | 13,028 |
| Chuck Ence CA and CO | Jan 29, 2024 | Buy | +10,800 | $3.65 | $39.42K | 10,800 |
| Sergio Traversa Chief Executive Officer, Director | Jan 29, 2024 | Buy | +31,541 | $3.71 | $117.02K | 175,565 |
| Cedric O'Gorman Chief Medical Officer | May 23, 2023 | Buy | +10,000 | $3.18 | $31.80K | 10,121 |
| Sergio Traversa Chief Executive Officer, Director | Dec 8, 2022 | Buy | +55,250 | $2.10 | $116.03K | 144,024 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Sale | −839 | $18.48 | $15.50K | 101,690 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Sale | −8,848 | $18.45 | $163.25K | 92,842 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Sale | −4,068 | $18.32 | $74.53K | 88,774 |
| Sergio Traversa Chief Executive Officer, Director | Jul 1, 2022 | Option exercise | +13,755 | $16.00 | $220.08K | 102,529 |
| Sergio Traversa Chief Executive Officer, Director | Jun 30, 2022 | Option exercise | +16,012 | $16.00 | $256.19K | 104,786 |
| Sergio Traversa Chief Executive Officer, Director | Jun 30, 2022 | Sale | −5,314 | $19.37 | $102.93K | 99,472 |
| Sergio Traversa Chief Executive Officer, Director | Jun 30, 2022 | Sale | −10,698 | $19.01 | $203.37K | 88,774 |
| Paul Edward Kelly Director | Apr 4, 2022 | Option exercise | +10,000 | $3.24 | $32.40K | 197,295 |
| Paul Edward Kelly Director | Apr 4, 2022 | Sale(10b5-1 plan) | −10,000 | $30.04 | $300.40K | 187,295 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 13,200 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 16,500 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 9,900 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 6,600 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 3,300 |
| Charles J. Casamento Director | Apr 1, 2022 | Sale(10b5-1 plan) | −3,300 | $29.00 | $95.70K | 0 |
| Charles J. Casamento Director | Apr 1, 2022 | Option exercise | +19,800 | $3.24 | $64.15K | 19,800 |
| Paul Edward Kelly Director | Jan 3, 2022 | Option exercise | −20,000 | $3.24 | $64.80K | 187,295 |
| Charles J. Casamento Director | Dec 3, 2021 | Gift | −10,000 | – | – | 0 |
| Charles J. Casamento Director | Dec 3, 2021 | Gift | +10,000 | – | – | 10,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
10.51%
11M shares short
Days to cover
6.4
At 2M shares a day
Change since last report
-11.0%
From 12M shares
Short volume, 20 days
46.8%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Relmada Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 300,758 shares on Oct 9, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| O'Gorman Cedric Officer | Feb 20, 2024 | 74,999 | $442.49K | Feb 20, 2024 | STOCK OPTION EXERCISE |
See a number that looks wrong?